CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 31 enrolled
Drug / intervention
suramin +2 moredrug
Likely dose
Suramin IV + paclitaxel IV; specific doses not stated in published recordAI-extracted
Key inclusion· 9
  • ✓Histologically or cytologically confirmed stage IIIB or IV metastatic breast cancer
  • ✓Prior paclitaxel or other taxanes in adjuvant or metastatic setting
  • ✓Up to two prior chemotherapy regimens for stage IIIB/IV MBC (Phase II)
  • ✓Measurable disease (Phase II only)
Key exclusion· 9
  • ✕Known brain metastases
  • ✕History of allergic reactions to Cremophor or similar compounds
  • ✕Concurrent uncontrolled illness precluding study compliance
  • ✕Ongoing or active infection

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00054028
NCT00054028Phase 2Completed
CompareCT.gov

A Phase I/II Study of Suramin in Combination With Paclitaxel in Advanced (Stage IIIB or IV) Metastatic Breast Cancer

National Cancer Institute (NCI)·interventional·Posted Feb 6, 2003·Updated Mar 17, 2015

In Brief

A Phase 2 clinical trial evaluating suramin, paclitaxel, and 1 other intervention for Recurrent Breast Cancer and 2 related conditions. Completed, enrolled 31 participants across 1 site.

Detailed Summary

This phase I/II trial studies the best dose of suramin when given together with paclitaxel in treating women with stage IIIB-IV breast cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Suramin may increase the effectiveness of paclitaxel by making tumor cells more sensitive to the drug.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 6, 2003
Enrollment StartDec 1, 2002
Primary CompletionMar 1, 2008
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 23.4 years ago

Interventions

suramindrug

Given IV

paclitaxeldrug

Given IV

pharmacological studyother

Correlative studies